{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:03:38Z","timestamp":1773083018068,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The \u2018chronic kidney disease\u2019 (CKD) definition that best outlines the complex syndrome commonly called \u2018kidney failure\u2019 has become a problem of World Public Health due to its incidence and prevalence and due to exponentially increasing costs in every part of the world. The progressive reduction in the glomerular filtration rate, as known, goes hand in hand with an increase in cardiovascular risk understood as fatal and non-fatal heart attack, stroke, heart failure, and mortality. Therefore, every effort must aim at preventing or slowing down the decline in renal function in order to reduce not only critical renal events (the need for dialysis or transplantation among the most dreadful) but also the incidence of cardiovascular events. Since the disease is asymptomatic for a long time (often its detection is occasional and done with guilty delay), it is clearly important to make a correct and early evaluation of renal function with appropriate methods. Furthermore, it is crucial to make an aetiological diagnosis, when it is possible, of CKD because this will allow for the most targeted therapy possible. For a long time, an effective approach for the majority of people with CKD could only count on strict control of the diabetic disease and its complications, optimization of high blood pressure values, and the mandatory use of drugs blocking the renin\u2013angiotensin\u2013aldosterone system, particularly in the presence of albuminuria. Over time, this strategy proved to be only partially effective and the majority of patients nonetheless showed a progressive worsening of renal function. Only recently have we had access to two classes of innovative drugs such as glyphozines and incretins which have established themselves on the therapeutic scene because they have shown to be able to slow down the progression of CKD, first in patients with type 2 diabetes and subsequently in patients with CKD whether or not they have diabetes. Unexpectedly and convincingly, they have also been shown to significantly impact cardiovascular prognosis. From initially antidiabetic drugs, their effectiveness has forced the medical iconography to enrich itself with a new therapeutic niche by rightly speaking of \u2018cardio-nephro-metabolic\u2019 drugs.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae123","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T12:22:17Z","timestamp":1734870137000},"page":"i149-i153","source":"Crossref","is-referenced-by-count":1,"title":["Can we slow down the decline in renal function?"],"prefix":"10.1093","volume":"27","author":[{"given":"Gennaro","family":"Cice","sequence":"first","affiliation":[{"name":"U.O.C. of Cardiology, Casilino Polyclinic , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-5286","authenticated-orcid":false,"given":"Leonardo","family":"Cal\u00f2","sequence":"additional","affiliation":[{"name":"U.O.C. of Cardiology, Casilino Polyclinic , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025021911173148400_suae123-B1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2025021911173148400_suae123-B2","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025021911173148400_suae123-B3","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2025021911173148400_suae123-B4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtration rate by differing measure, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease","volume":"25","author":"Lees","year":"2019","journal-title":"Nat Med"},{"key":"2025021911173148400_suae123-B5","doi-asserted-by":"crossref","first-page":"B50","DOI":"10.1093\/eurheartjsupp\/suad067","article-title":"Treating chronic kidney disease to reduce cardiovascular risk","volume":"25","author":"Cice","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"2025021911173148400_suae123-B6","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/ASG\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults: ACC\/AHA Task Force on Clinical Pratice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertens"},{"key":"2025021911173148400_suae123-B7","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2025021911173148400_suae123-B8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2025021911173148400_suae123-B9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"REIN-2: multicenter, randomized, controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2025021911173148400_suae123-B10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025021911173148400_suae123-B11","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibitor for treatment of kidney diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2025021911173148400_suae123-B12","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2215\/CJN.09110914","article-title":"Meta-analysis of the effect of dietary sodium restriction with or without concomitant renin angiotensin aldosterone antagonist-inhibiting treatment of albuminuria","volume":"10","author":"D\u2019Elia","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025021911173148400_suae123-B13","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralcorticoid receptor antagonist in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2025021911173148400_suae123-B14","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical Practice Guidelines on management of patients with diabetes and CKD stage 3b or higher (eGFR&lt;45ml\/min)","volume":"30","author":"Guideline development group","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025021911173148400_suae123-B15","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2025021911173148400_suae123-B16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control in patients with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials","volume":"5","author":"Zougas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025021911173148400_suae123-B17","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacological approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","author":"America Diabetes Association Professional Pratice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2025021911173148400_suae123-B18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2i for prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025021911173148400_suae123-B19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025021911173148400_suae123-B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025021911173148400_suae123-B21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular mortality and kidney outcome with GLP1 receptor agonist in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025021911173148400_suae123-B22","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of Major adverse cardiovascular and renal outcomes in type 2 diabetes Mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2025021911173148400_suae123-B23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjcard.2022.07.012","article-title":"Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure","volume":"181","author":"Lopez","year":"2022","journal-title":"Am J Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i149\/61968379\/suae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i149\/61968379\/suae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:17:50Z","timestamp":1739963870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_1\/i149\/8023295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae123","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}